Quinoclamine is a naphthoquinone derivative and is an NF-κB inhibitor.

Quinoclamine induces the differentiation of U-937 cells into macrophage-like cells. Quinoclamine inhibits NF-κB activities in HepG2 cells (IC50: 1.7 μM). Quinoclamine inhibits induced NF-κB activities in lung and breast cancer cell lines. Quinoclamine affects the expression levels of genes involved in cell cycle or apoptosis. Quinoclamine down-regulates the expressions of UDP glucuronosyltransferase genes involved in phase II drug metabolism. Quinoclamine (1-4 μM; 30 minutes ) inhibits endogenous NF-κB activity in HepG2 cells through the inhibition of IκB-α phosphorylation and p65 translocation [1][2].